Syndax Pharma (SNDX) and Incyte (INCY) said Monday that a mid-stage trial for axatilimab a candidate for chronic graft-versus-host disease succeeded. Read more here.
Incyte (INCY) announced Friday that a group of experts in the EU recommended the approval of ruxolitinib cream for non-segmental vitiligo with facial involvement. Read the full story here.
Incyte Corporation INCY recently announced positive top-line results from the late-stage TRuE-AD3 study on Opzelura (ruxolitinib cream). TRuE-AD3 (NCT04921969) is a randomized, double-blind, vehicle-controlled phase III study evaluating the safety and efficacy of ruxolitinib cream compared to vehicle (non-medicated cream) in children with atopic dermatitis (AD). The study enrolled more than 300 patients (age ≥2…
Incyte's (INCY) Opzelura (ruxolitinib) was found to be effective in treating pediatric atopic dermatitis in a phase 3 trial. Read more here.
C hip-making giant Nvidia (NVDA) could gain another 15% or more this year as investors continue to back the Artificial Intelligence (AI) revolution, analysts and investors said. Up nearly 200% this year, Nvidia soared last month after providing a ‘jaw-dropping’ second-quarter revenue guidance that was 50% higher than Wall Street expected. This came amid break-neck…
Given that the biotech sector is rapidly expanding with robust demand, technology advancements, and government initiatives, fundamentally strong biotech stocks Incyte (INCY), Corcept Therapeutics (CORT), and Entrada Therapeutics (TRDA) look poised to generate significant returns. Hence, these stocks could be solid additions to your portfolio. Read on. The biotech industry is well-positioned to thrive,…
The biotech industry is well-positioned to thrive, owing to inelastic demand, rapid developments, and government initiatives. So, quality biotech stocks Incyte Corporation (INCY), Corcept Therapeutics Incorporated (CORT), and Entrada Therapeutics, Inc. (TRDA) could be worth buying.
The industry is consistently evolving with advanced technologies like AI. The global Generative AI in Biotech Market is estimated…
BofA Securities has downgraded Incyte Corp. (INCY) to neutral from buy saying that it sees slower growth in the near term for Opzelura (ruxolitinib). Read more here
Key Insights Incyte's estimated fair value is US$149 based on 2 Stage Free Cash Flow to Equity Current share price of US$75.34 suggests Incyte is potentially 49% undervalued Analyst price target for INCY is US$89.10 which is 40% below our fair value estimate Does the May share price for Incyte Corporation…
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms). Therefore, finding a cure would…
An Incyte cancer drug that was turned down by the FDA two years ago was granted an unexpected approval Wednesday in a different type of cancer, a regulatory decision that now pits the new product in competition with already entrenched immunotherapies from Merck and partners Pfizer and EMD Serono.
Accelerated approval for the Incyte drug,…
Incyte (INCY) announced Wednesday that the FDA cleared its intravenous PD-1 inhibitor Zynyz for patients with Merkel cell carcinoma, a rare form of skin cancer. Read the full story here.